What does “histamine biosynthesis” mean in US patent applications?
In US patent filings, “histamine biosynthesis” usually refers to making histamine inside the body (or in a biological/biotech system). That typically centers on pathways and enzymes involved in converting histidine to histamine, most commonly the enzyme histidine decarboxylase (HDC), plus upstream regulation of histidine availability and downstream histamine receptor signaling. Patents may describe methods, engineered cells/microbes, diagnostics, or drug candidates that alter one or more steps in this pathway.
What kinds of claims show up in patents about histamine biosynthesis?
Common claim themes include:
- Inhibiting histidine decarboxylase (HDC) activity to reduce histamine formation.
- Reducing histamine release or downstream signaling triggered by newly formed histamine.
- Modifying cells (for example, immune cells, engineered microbiomes, or other biological production systems) to change histamine levels.
- Assays/diagnostics that measure histamine production rates as a biomarker of pathway activity.
- Therapeutic uses of compounds that regulate histamine biosynthesis-related steps.
These filings often cover both the biochemical mechanism and a practical end-use (treating inflammatory conditions, allergies, or other histamine-linked conditions), but the exact disease focus depends on the application.
Are there specific “US patent applications” that list histamine biosynthesis?
The phrase “histamine biosynthesis” can appear in many contexts across different US applications, so the most accurate way to find the right ones is to search by:
- Keywords: “histamine biosynthesis,” “histidine decarboxylase,” “HDC,” “histidine decarboxylase inhibitor,” and “histamine production”
- Patent databases and full-text search (USPTO Patent Public Search, Google Patents, Lens.org)
- Assignee/company names (if you already know the target developer)
If you share the applicant name, a patent number/publication number, or a keyword phrase you saw in a specific document, I can help narrow down the likely subject matter and what the claims are getting at.
How do patents about histamine biosynthesis relate to existing drugs?
Many therapies that reduce histamine effects do it downstream (for example, by blocking histamine receptors). Patents focused on biosynthesis tend to be more upstream, aiming to lower how much histamine is produced in the first place (often by targeting HDC or pathway regulation). The distinction matters for claim scope: receptor antagonists tend to look different from HDC-targeting applications.
Can a US patent application be about histamine production in microbes or biotech?
Yes. “Biosynthesis” is not limited to human physiology. Some applications cover engineered microorganisms, fermentation processes, or synthetic biology approaches where histamine (or histamine-relevant intermediates) are produced or reduced in controlled systems. In those cases, the same chemistry exists, but the claims focus on production methods, strains, culture conditions, or engineered genetic constructs.
What to check in a US application to confirm it’s truly about biosynthesis (not just histamine treatment)?
When you open a specific publication, check whether it includes:
- An enzyme or pathway step (for example, HDC/histidine decarboxylase).
- Methods that change production rate or intracellular histamine formation.
- Process claims describing production/engineering conditions.
- Experimental data measuring histamine levels after pathway modulation.
If it only discusses antihistamines or receptor blocking without altering production, it may be categorized under histamine signaling rather than histamine biosynthesis.
---
Sources
No source link was provided with your question, and I don’t have enough identifying detail to pull a specific DrugPatentWatch.com or USPTO record for “histamine biosynthesis.” If you tell me the publication number (like US20xx/xxxxx) or the applicant/company, I can target the exact US patent application content.